SCHEMBL279990

SCHEMBL279990

Cc1ccc(C(=O)CCCCN2CCSCC2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.49
HRH2 P25021 2/20 0.48
HRH1 P35367 2/20 0.48
DRD2 P14416 2/20 0.39
DRD4 P21917 1/20 0.39
DRD3 P35462 1/20 0.39
DAO P14920 1/20 0.39
ALDH1A1 P00352 2/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
SLC6A4 P31645 1/20 0.37
HTR7 P34969 1/20 0.37
POLB P06746 1/20 0.36
HPGD P15428 1/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279625 0.85 HTR1A (0.48) HTR1AHRH2HRH1ALDH1A1RAB9A
SCHEMBL279637 0.81 ALDH1A1 (0.49) HTR1ADAOALDH1A1MAPK1HTT
SCHEMBL280030 0.81 ALDH1A1 (0.50) HTR1AHRH2HRH1ALDH1A1RAB9A
SCHEMBL22721115 0.77 DAO (0.57) HTR1ADAOALDH1A1MAPK1RAB9A
SCHEMBL279694 0.75 HTR1A (0.57) HTR1AALDH1A1HTTRAB9ATSHR
SCHEMBL9378748 0.75 DAO (0.50) HTR1AHRH2HRH1DAOALDH1A1
SCHEMBL15979700 0.74 DAO (0.61) HTR1ADAOALDH1A1MAPK1RAB9A
SCHEMBL280123 0.71 DAO (0.55) HTR1ADAOALDH1A1MAPK1RAB9A
SCHEMBL10972012 0.71 DAO (0.50) HTR1AHRH2HRH1DAOALDH1A1
Hydrochloric Acid SCHEMBL5373255 0.70 ALDH1A1 (0.62) HTR1AALDH1A1HTR7POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HTR1A 1005/4885HRH2 530/4885HRH1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.